Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

21 May 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

Piramal Articles

Fujifilm JV plans bevacizumab biosimilar; Fujifilm Diosynth Bio alliance with Piramal for ADCs

25 October 2012

Piramal buys molecular imaging portfolio from Bayer

16 April 2012

Solvay costs and Meridia withdrawal take heavy toll on Abbott Labs 3rd-qtr 2010 results

21 October 2010

Abbott Labs to buy Piramal domestic formulation business for $3.72 billion; to become number one drugmaker in India

21 May 2010

Sanofi-Aventis to take control of Poland’s Nepentes; cited as buyer for Piramal; names new chairman

19 May 2010

India’s Piramal to buy Bharat Serums injectable anesthetics business

26 April 2010

Showing 1-6 of 6 articles

Go to beginningPrevious
  • 1
NextGo to end
  • Hot Topics
  • Most Read
  • Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
  • Elan makes "transformational" acquisitions and a divestment
  • HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
  • Is failure to adopt business process management putting the pharma industry at risk?
  • Greek research-based drugmaker group AIFD challenges generics assumptions in Draft Patent Law
  • Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
  • Elan makes "transformational" acquisitions and a divestment
  • HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
  • Is failure to adopt business process management putting the pharma industry at risk?
  • Greek research-based drugmaker group AIFD challenges generics assumptions in Draft Patent Law

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS